Therapeutic effect of the combined use of growth hormone releasing peptide-6 and epidermal growth factor in an axonopathy model.

Del Barco DG, Pérez-Saad H, Rodríguez V, Marín J, Falcón V, Martín J, Cibrian D, Berlanga J

Neurotoxicity research19 Feb 2010Cited by 14 (Europe PMC)

PMID20169434DOI10.1007/s12640-010-9160-8PepBankPUB-20169434

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

01AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In mice with 1,2 DAB axonopathy, daily EGF or GHRP‑6 given separately did not accelerate recovery of the affected parameters, except for the gait pattern.
In plain wordsIn mice with nerve damage, EGF or GHRP‑6 given alone did not speed recovery of most measures.
Peptide
GHRP-6
Outcome
No significant changeRecovery of behavioral and electrophysiological parameters with separate EGF and GHRP-6, except gait
Study
Mousen: not reported in source
1,2 diacetylbenzene (1,2 DAB) proximal axonopathy
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Daily administration of the separate compounds did not accelerate the recovery of the affected parameters, except for the gait pattern.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of the present work was to evaluate the separate and combined effects of both peptides in an experimental animal model of ALS, the proximal axonopathy induced by 1,2 diacetylbenzene (1,2 DAB) in mice.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-2016943401
02AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In mice with 1,2 DAB axonopathy, daily EGF or GHRP‑6 given separately accelerated recovery of the gait pattern.
In plain wordsIn mice with nerve damage, EGF or GHRP‑6 given alone sped up recovery of the walking pattern.
Peptide
GHRP-6
Outcome
IncreaseGait pattern recovery with separate EGF and GHRP-6
Study
Mousen: not reported in source
1,2 diacetylbenzene (1,2 DAB) proximal axonopathy
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
Daily administration of the separate compounds did not accelerate the recovery of the affected parameters, except for the gait pattern.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of the present work was to evaluate the separate and combined effects of both peptides in an experimental animal model of ALS, the proximal axonopathy induced by 1,2 diacetylbenzene (1,2 DAB) in mice.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-2016943402
03AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In mice with 1,2 DAB axonopathy, combined EGF and GHRP‑6 treatment gave significant improvement in behavioral parameters.
In plain wordsIn mice with nerve damage, EGF and GHRP‑6 together improved behavior tests.
Peptide
GHRP-6
Outcome
IncreaseBehavioral parameters with combined EGF and GHRP-6
Study
Mousen: not reported in source
1,2 diacetylbenzene (1,2 DAB) proximal axonopathy
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
The combined treatment produced significant improvement in behavioral parameters
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of the present work was to evaluate the separate and combined effects of both peptides in an experimental animal model of ALS, the proximal axonopathy induced by 1,2 diacetylbenzene (1,2 DAB) in mice.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-2016943403
04AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In mice with 1,2 DAB axonopathy, combined EGF and GHRP‑6 treatment improved electrophysiological recovery, particularly in the proximal CMAP segment.
In plain wordsIn mice with nerve damage, EGF and GHRP‑6 together improved nerve signal recovery, mostly in the upper leg.
Peptide
GHRP-6
Outcome
IncreaseElectrophysiological recovery (CMAP) with combined EGF and GHRP-6
Study
Mousen: not reported in source
1,2 diacetylbenzene (1,2 DAB) proximal axonopathy
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
as well as in electrophysiological recovery, particularly in the proximal segment of CMAP.
1 context sentence(design, population, supporting numbers)
Summary · context
The aim of the present work was to evaluate the separate and combined effects of both peptides in an experimental animal model of ALS, the proximal axonopathy induced by 1,2 diacetylbenzene (1,2 DAB) in mice.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-2016943404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.